Table 2 Study population
PanC (No. 47) | CS (No. 51) | |
|---|---|---|
Gender, N (%) | ||
Male | 25 (53.2) | 58 (54.9) |
Female | 22 (46.8) | 23 (45.1) |
Age, median (IQR) | 60 (49–68) | 63 (57–68) |
< 55 years, N (%) | 24 (51.1) | 9 (17.6) |
≥ 55 years, N (%) | 23 (48.9) | 42 (82.4) |
Body Mass Index, N (%)* | ||
≤ 30 | 40 (87) | 40 (78.4) |
> 30 | 6 (13) | 11 (21.6) |
Smoker, N (%) | ||
No | 12 (25.5) | 17 (33.3) |
Current | 17 (36.2) | 21 (41.2) |
Past | 18 (38.3) | 13 (25.5) |
Alcohol intake, N (%) | ||
No | 16 (34) | 16 (31.4) |
Moderate | 27 (57.5) | 28 (54.9) |
Heavy | 4 (8.5) | 7 (13.7) |
Diabetes, N (%) | ||
No | 31 (66) | 24 (47.1) |
Yes | 16 (34) | 17 (52.9) |
Early-Onset | 7 (43.8) | 16 (59.3) |
Family history of cancer, N (%)* | ||
Pancreas | 25 (53.2) | 20 (40) |
Breast | 7 (14.9) | 4 (8) |
Endometrium | 6 (12.8) | 0 |
Colon | 5 (10.6) | 6 (12) |
Melanoma | 2 (4.3) | 1 (2.0) |
Other | 19 (40.4) | 13 (26) |
Pre-operative classification, N (%)* | ||
Resectable | 11 (24.4) | |
Locally advanced | 15 (33.3) | |
Metastatic | 19 (42.2) | |
Surgery, N (%)* | ||
No | 32 (69.6) | |
Yes | 14 (30.4) | |
Tumor location, N (%)* | ||
Head | 35 (79.5) | |
Body/Tail | 9 (20.5) | |
Tumor stage, N (%)* | ||
IA | 1 (2.3) | |
IIB | 14 (31.8) | |
III | 8 (18.2) | |
IV | 21 (47.7) | |
Adjuvant therapy, N (%)* | ||
No | 9 (20.5) | |
Yes | 35 (79.5) |